BCM
CRBU icon

Beaumont Capital Management’s Caribou Biosciences CRBU Stock Holding History

Beaumont Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,825
Closed -$18.8K – 61
2024
Q4 		$18.8K Sell
11,825
-4,495
-28% -$9.04K 0.01% 48
2024
Q3 		$32K Buy
+16,320
New +$33.4K 0.02% 48

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Beaumont Capital Management's CRBU Position: Q1 2025 in Review

Beaumont Capital Management sold out of Caribou Biosciences (CRBU) in Q1 2025, closing a stake of 11,825 shares — an estimated $18.8K sold.

Beaumont Capital Management first reported a position in CRBU in Q3 2024 and held it in 2 quarters. The position peaked at $32K in Q3 2024. 131 funds tracked by Wall St. Rank hold CRBU as of Q1 2025.

  • Beaumont Capital Management reported no remaining Caribou Biosciences position as of Q1 2025 after selling out during the quarter.
  • Beaumont Capital Management sold 11,825 Caribou Biosciences shares in Q1 2025, an estimated $18.8K.
  • Beaumont Capital Management first reported a position in Caribou Biosciences in Q3 2024 and held it in 2 quarters.
  • Beaumont Capital Management's Caribou Biosciences position peaked at $32K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2025.

Based on Beaumont Capital Management's 13F filing for Q1 2025, filed 15 May 2025.